Nature Communications | Phase Ib/II Clinical Study of the Multi-Kinase Inhibitor Tinengotinib as Monotherapy or in Combination with Atezolizumab for Advanced Solid Tumors

This study provides key clinical evidence for the treatment strategies of biliary tract cancer, particularly demonstrating significant antitumor activity in patients with FGFR2 fusion-positive tumors who have progressed on prior FGFR inhibitor therapy, suggesting that multi-targeted inhibition may represent an important approach to overcoming resistance.

 

Literature Overview

The article titled “The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial,” published in Nature Communications, systematically investigates the safety and preliminary efficacy of the multi-kinase inhibitor tinengotinib in patients with advanced solid tumors. The study design includes two cohorts: monotherapy and combination with immune checkpoint inhibitors, with a focus on FGFR-driven cancers such as biliary tract cancer. The results not only confirm the tolerability of tinengotinib but also reveal its significant antitumor activity in specific molecular subtypes, laying a solid foundation for further clinical development.

Background Knowledge

Biliary tract cancer (BTC) is a highly heterogeneous malignancy with poor prognosis and limited treatment options. In recent years, FGFR2 fusions have been identified as key oncogenic drivers in approximately 10–15% of intrahepatic cholangiocarcinomas, making them important therapeutic targets. Although FGFR inhibitors such as pemigatinib and futibatinib have been approved for first-line treatment, most patients eventually progress due to acquired resistance (e.g., kinase domain mutations in FGFR2). Additionally, the immunologically “cold” tumor microenvironment limits the efficacy of immune checkpoint inhibitors (ICIs) as monotherapy in biliary tract cancer. Therefore, overcoming resistance and enhancing antitumor immune responses remain central challenges in current research.

The rationale of this study is to develop a multi-pathway inhibitor—tinengotinib—with activity against FGFR1–3, JAK1/2, VEGFRs, and Aurora A/B kinases. By inhibiting FGFR signaling, it directly kills tumor cells; simultaneously, blockade of VEGFR and Aurora A promotes vascular normalization and modulates the immune microenvironment, thereby enhancing T-cell infiltration and function. Combining with the PD-L1 inhibitor atezolizumab theoretically enables synergistic antitumor effects. This strategy aims to overcome the limitations of single-agent targeted therapy and activate immune responses in “cold” tumors, offering a new therapeutic avenue for biliary tract cancer patients.

 

 

Research Methods and Experiments

This study employed an open-label, multicenter phase Ib/II design, divided into two arms: Arm A evaluated tinengotinib monotherapy in patients with advanced solid tumors (n=53), while Arm B assessed tinengotinib in combination with atezolizumab in patients with advanced biliary tract cancer (n=31). The phase Ib portion used a standard 3+3 dose-escalation design to determine safety, tolerability, dose-limiting toxicities (DLTs), and the maximum tolerated dose (MTD). The phase II portion expanded the cohorts, with primary endpoints of objective response rate (ORR) and disease control rate (DCR), and secondary endpoints including PFS, OS, and pharmacokinetic (PK) analysis. All patients underwent NGS testing for FGFR status, and efficacy was evaluated per RECIST 1.1 criteria, with iRECIST additionally applied in Arm B to identify immune-related pseudoprogression.

Key findings include: 1) No DLTs were observed during dose escalation, and MTD was not reached; tinengotinib 10 mg QD was selected as the recommended phase II dose; 2) In Arm A, cholangiocarcinoma patients (n=13) achieved an ORR of 30.8%, with particularly high efficacy in those with FGFR2 fusions previously treated with FGFR inhibitors (n=3), achieving an ORR of 66.7%; 3) In Arm B, the combination therapy yielded an ORR of 22.6% in biliary tract cancer patients, with an ORR of 20.0% and DCR of 75.0% even among patients previously treated with ICIs (n=20); 4) PK analysis demonstrated stable drug exposure, supporting once-daily dosing.

Key Conclusions and Perspectives

• Tinengotinib monotherapy shows significant antitumor activity in patients with FGFR2 fusion-positive cholangiocarcinoma, achieving a 66.7% ORR even after failure of prior FGFR inhibitor therapy, suggesting potential to overcome common resistance mutations such as N550K and V565F, providing direct evidence for subsequent development of resistance models
• Combination with atezolizumab maintains a 20.0% ORR in ICI-pretreated patients, indicating that tinengotinib may enhance T-cell infiltration by modulating the tumor microenvironment (e.g., via inhibition of VEGFR and Aurora A), thereby reversing immune resistance, supporting further exploration of its immunomodulatory role in “cold” tumors
• The most common ≥grade 3 adverse events were hypertension and hematologic toxicity, with no typical hyperphosphatemia associated with selective FGFR inhibitors, suggesting a more favorable safety profile suitable for long-term administration, offering guidance for designing safer clinical regimens
• Pharmacokinetic data support once-daily oral dosing, with steady-state plasma concentrations achieved by day 15, providing reliable parameters for future clinical pharmacology and dosing optimization

Research Significance and Prospects

This study provides a new direction for precision therapy in biliary tract cancer, particularly demonstrating substantial potential in addressing the unmet need for effective treatments after resistance to FGFR inhibitors. Its multi-targeted profile not only enhances antitumor efficacy but may also improve immune response by modulating the vascular and immune microenvironment, highlighting its unique advantages in combination strategies.

From a drug development perspective, these findings support advancing to randomized phase III trials to define its role in second-line or later settings. Additionally, biomarker studies should be strengthened, such as dynamic monitoring of FGFR2 mutations in ctDNA, to identify optimal responder populations. Furthermore, establishing PDX or organoid models for in vitro efficacy validation will help elucidate its mechanisms of action and resistance.

 

 

Conclusion

This study systematically evaluates the clinical potential of the multi-kinase inhibitor tinengotinib in advanced solid tumors, particularly highlighting its remarkable efficacy in biliary tract cancer. Achieving a 66.7% objective response rate in patients with FGFR2 fusion-positive tumors who have failed prior FGFR inhibitor therapy offers a new treatment option for this difficult-to-treat population. The combination with atezolizumab maintains a 20.0% response rate in ICI-pretreated patients, suggesting enhanced immune response through modulation of the tumor microenvironment. From bench to bedside, this study not only validates the feasibility of multi-targeted inhibition strategies but also establishes a solid foundation for subsequent disease modeling, efficacy evaluation, and translational research. Future efforts should focus on developing companion diagnostics, optimizing combination regimens, and leveraging humanized mouse models to deeply investigate its immunomodulatory mechanisms, thereby advancing precision therapy for biliary tract cancer.

 

Panpan Zhang, Zuoxing Niu, Hongqian Guo, Jun Zhou, and Lin Shen. The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial. Nature Communications.